DBTX Stock Overview
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Decibel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.91 |
| 52 Week High | US$5.40 |
| 52 Week Low | US$1.61 |
| Beta | -0.40 |
| 1 Month Change | -3.91% |
| 3 Month Change | 40.29% |
| 1 Year Change | 65.88% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.77% |
Recent News & Updates
Recent updates
Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation
Aug 10
Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?
Feb 07Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial
Oct 17We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully
Sep 01Decibel Therapeutics: Gene Therapies For Hearing Loss
Jul 06Shareholder Returns
| DBTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -0.4% |
| 1Y | 65.9% | -2.7% | 24.8% |
Return vs Industry: DBTX exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: DBTX exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| DBTX volatility | |
|---|---|
| DBTX Average Weekly Movement | 25.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DBTX's share price has been volatile over the past 3 months.
Volatility Over Time: DBTX's weekly volatility has increased from 17% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 68 | Laurence Reid | www.decibeltx.com |
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company’s product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.
Decibel Therapeutics, Inc. Fundamentals Summary
| DBTX fundamental statistics | |
|---|---|
| Market cap | US$124.35m |
| Earnings (TTM) | -US$63.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs DBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$63.39m |
| Earnings | -US$63.39m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DBTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/06 17:55 |
| End of Day Share Price | 2023/09/22 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Decibel Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Matthew Luchini | BMO Capital Markets Equity Research |